REGN Stock Analysis — Regeneron Pharmaceuticals
Sector: Healthcare
AI Verdict
Regeneron trades at 14.1x next year's earnings with nearly 40% EPS growth expected—cheap for the growth on offer, but the extreme RSI means the stock is vulnerable to a sharp near-term pullback if expectations slip.
Competitive Moat
Regeneron specializes in monoclonal antibody therapies and has a defensible moat through its proprietary VelociSuite technology, which accelerates the discovery and development of new biologics. Its deep pipeline and in-house R&D platform create high barriers to entry for competitors.
Summary
Regeneron's 39.7% forward EPS growth estimate is driving attention as the stock trades at a steep discount to sector P/E norms.
Where It Stands
Shares are up 42.10% over the past year with an RSI of 91.5 (deeply overbought) and trade at 14.1x forward earnings versus the healthcare sector median of 22x.
Key Metrics
- RSI: 91.5 — Overbought
- Trailing P/E: 19.7x
- Forward P/E: 14.1x
- PEG Ratio: 0.50
- Earnings Growth: +0.4%
- Revenue Growth: +0.1%
- Market Cap: $82.2B
- Dividend Yield: 0.00%
- 1-Year Return: 42.10%
- 52-Week High: $821.11
- 52-Week Low: $541.00
Analyst Consensus
26 Buy · 11 Hold · 0 Sell (37 analysts)
Bull Case
With 39.7% forward EPS growth expected and a forward P/E of just 14.1x, you're paying a low price for rapid earnings expansion if Regeneron's biologics pipeline continues to deliver.
Bear Case
An RSI of 91.5 signals extreme overbought territory, so even a modest pullback to neutral RSI levels could erase a chunk of the recent 42.10% gain.
Catalyst to Watch
Upcoming clinical trial results or FDA approvals for pipeline drugs could either reinforce the growth narrative or trigger a sharp correction.